 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm, BR790 / Jiangxi Qingfeng Pharma
New P1/2 trial, Combination therapy, Metastases: BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 8, 2023
P1/2, N=90, Not yet recruiting, Sponsor: Shanghai Gopherwood Biotech Co., Ltd.
- | Tevimbra (tislelizumab) / BeiGene, BR790 / Jiangxi Qingfeng Pharma
New P1/2 trial, Combination therapy, Metastases: Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 18, 2022
P1/2, N=160, Recruiting, Sponsor: Shanghai Gopherwood Biotech Co., Ltd.
- || BR790 / Jiangxi Qingfeng Pharma
New P1 trial, Monotherapy, Metastases: A Phase I Study of BR790 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - May 17, 2021
P1, N=48, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.